Impact BioMedical Celebrates a Milestone in Patent Issuance
Impact BioMedical Inc. (NYSE: IBO) is excited to share a significant achievement regarding its innovative Linebacker™ technology platform. Recently, the Canadian Intellectual Property Office granted Canadian Patent #3,024,728 for Electrophilically Enhanced Phenolic Compounds for Treating Inflammatory Related Diseases and Disorders. This patent encompasses groundbreaking enhanced phenolic compounds and their pharmaceutical compositions designed to treat various inflammatory diseases.
Understanding the Linebacker™ Technology
The Linebacker™ technology stands as a collection of small molecule compounds strategically developed to target key pathways involved in the inflammatory process. The objective is to potentially reduce inflammation while offering symptomatic relief. A crucial aspect of this platform is its aim to lessen the side effects often linked to conventional anti-inflammatory medications.
Wider Implications of the Patent
The newly awarded patent describes a methodology utilizing a formulation from the Linebacker™ range of novel compounds. This formulation shows promise in inhibiting inflammatory responses, potentially benefiting conditions like arthritis, asthma, and inflammatory bowel disease. This achievement represents the first issuance of a Linebacker™ patent in Canada, underlining Impact BioMedical’s dedication to innovating unique technologies that address pressing healthcare needs.
Market Perspective and Future Aspirations
Frank D. Heuszel, the CEO of Impact BioMedical, shared insights on the expanding market for inflammatory disease treatments, estimated at around $7 billion in 2022. Heuszel emphasized that this patent issuance is a pivotal step in enhancing the company's intellectual property portfolio and showcases the transformative potential of their Linebacker™ technology, both commercially and therapeutically.
About Impact BioMedical Inc.
Impact BioMedical Inc. focuses on identifying, validating, and patenting pioneering science and technologies that lead to groundbreaking solutions in human healthcare and wellness. Once innovations are developed, the company engages in licensing, co-development, and establishing partnerships to bring these solutions to the market efficiently. For more detailed information about the company, you can visit their website.
Exploring Linebacker™ Technology Further
The Linebacker™ platform is centered on small molecule electrophilically enhanced polyphenols. These compounds hold potential applications across various fields, including oncology for solid tumors, inflammatory disorders, and neurology. Derived from natural sources such as nuts, vegetables, and berries, these polyphenols, specifically myricetin, have been modified to enhance their properties.
Collaboration for Development
Impact BioMedical has licensed its Linebacker™ -1 and Linebacker™ -2 compounds to ProPhase Laboratories for their development and commercialization. This partnership reflects the company’s strategic approach to advancing their technologies and ensuring they reach those who need them the most.
Contact and Investor Relations
The company maintains an open line for communication regarding inquiries. Interested parties can reach out via email for further information.
Frequently Asked Questions
What is the significance of the Canadian patent for Impact BioMedical?
The Canadian patent allows Impact BioMedical to protect its innovative Linebacker™ technology and enhances its intellectual property portfolio, crucial for advancing treatment options for inflammatory diseases.
What conditions does the Linebacker™ technology target?
The Linebacker™ technology is focused on targeting various inflammatory conditions such as arthritis, asthma, and inflammatory bowel disease.
Who is the CEO of Impact BioMedical?
Frank D. Heuszel serves as the CEO of Impact BioMedical, guiding the company’s strategic vision and market developments.
What are the future applications of Linebacker™ technology?
Future applications of Linebacker™ technology are anticipated in oncology, inflammatory disorders, and neurology, expanding its impact on healthcare.
How does Impact BioMedical work with partners?
Impact BioMedical collaborates through licensing, co-development, and joint ventures to bring its innovative healthcare solutions to the market effectively.
